Two of the most prestigious life science industry awards were won by GlaxoSmithKline and QuintilesIMS.on Wednesday at the 12th annual international Scrip Awards in London.

GlaxoSmithKline’s Newborn Survival Project was named Community Partnership of the Year winner.

And QuintilesIMS earned the Best Full-service Provider Contract Research Organization, or CRO, honor. It’s the sixth time over the past eight years that Quintiles won the award. Quintiles recently merged with IMS in a $17 billion deal.

The GSK project

​GSK, which has a major presence in the Triangle region, launched the Save the Children partnership in 2013.

“The partnership goes well beyond the traditional charity corporate fundraising model,” GSK points out at its website.

“We are combining our capabilities in R&D, supply chain, procurement and vaccines with Save the Children’s expertise working with the most vulnerable children.”

Focal points of the program include:

  • Improving access to basic healthcare – prevention and treatment – where the need is greatest
  • Training and equipping health workers in the poorest communities
  • Developing child-friendly medicines
  • Working at local and global levels to call for stronger child health policies

GSK says it has “reached” more than 1.3 million children through the program with more than 23,500 children under age 5 having receive immunizations.

“[O]ver 125,000 children have been treated for diarrhoea, malaria or pneumonia, and over one million children have been screened for malnutrition,” GSK adds.

Watch a video about the project at:

​Read more about the project at:

QuintilesIMS CRO award

​QuintilesIMS, which operates one of its two headquarters in Durham, was named top CRO again based on an independent judges panel review of data across a broad spectrum.

“Our judges felt QuintilesIMS was a worthy winner of this year’s Best Contract Research Organization trophy, one of the most competitive categories at the Scrip Awards,” said Mike Ward, global director of content for Informa Pharma Insights portfolio.  “Despite plenty of competition, QuintilesIMS continues to set the pace.”

Criteria include quality of relationships CROs have built with clients and innovative approaches to the use of data management and patient recruitment strategies.

“We are delighted to receive this distinction once again this year,” said Cynthia Verst, president, Clinical Operations, QuintilesIMS. “The Scrip Awards are among the most sought after in the biopharmaceutical industry, and we are extremely pleased to have been honored with this award. Being selected for this recognition reinforces the impact we have in the biopharmaceutical industry as well as the important role we serve in creating solutions that help our clients drive healthcare forward.”